WHO ICTRP trial
Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine…
ACTRN12622000638730 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12622000638730 |
|---|---|
| Public title | Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine (ASMQ) and Artesunate-Pyronaridine (ASP) for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Cambodia |
| Scientific title | Clinical and parasitological efficacy of artesunate-amodiaquine over 28 days in the treatment of uncomplicated falciparum malaria in Cambodia |
| Primary sponsor | Ministry of Health |
| Secondary sponsors | National Center for Malaria Control, Parasitology and Entomology |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 / Phase 3 |
| Countries | Cambodia |
| Conditions | Patients with Plasmodium falciparum infection;Patients with Plasmodium vivax infection; Patients with Plasmodium falciparum infection Patients with Plasmodium vivax infection;Infection - Other infectious diseases |
| Interventions | ASMQ (Artesunate + Mefloquine co-formulated). The adult dose tablet contains 100mg Artesunate plus 220mg Mefloquine and the pediatric tablet contain 55mg Artesunate plus 55 mg Mefloquine. ASP (Artesunate + Pyronaridine/ Pyramax): Adults and… |
| Registration date | Feb 5, 2022 |
| Target size | 120 |
| Secondary IDs | 120NECHR |
| Registry page | anzctr.org.au |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: